tetano
Editor, Senior Moderator
Vascul Pharmacol
. 2021 Jun 3;106883.
doi: 10.1016/j.vph.2021.106883. Online ahead of print.
Thromboprophylaxis strategies to improve the prognosis of COVID-19
Laurent Bertoletti[SUP] 1 [/SUP], Behnood Bikdeli[SUP] 2 [/SUP], Stéphane Zuily[SUP] 3 [/SUP], Marc Blondon[SUP] 4 [/SUP], Patrick Mismetti[SUP] 5 [/SUP]
Affiliations
Abstract
The outbreak of 2019 novel coronavirus disease (Covid-19) has deeply challenged the world population, but also our medical knowledge. Special attention has been paid early to an activation of coagulation, then to an elevated rate of venous thromboembolism (VTE) in patients hospitalized with severe COVID-19. These data suggested that anticoagulant drugs should be evaluated in the treatment of patients with COVID-19. The publication of unexpected high rates of VTE in patients hospitalized with COVID-19, despite receiving thromboprophylaxis, open the way to dedicated trials, evaluating modified regimens of thromboprophylaxis. Moreover, the further improvement in our comprehension of the disease, particularly the pulmonary endothelial dysfunction increased the hope that anticoagulant drugs may also protect patients from pulmonary thrombosis. In this comprehensive review, we cover the different situations where thromboprophylaxis standard may be modified (medically-ill inpatients, ICU inpatients, outpatients), and describe some of the current randomized controls trials evaluating new regimens of thromboprophylaxis in patients with COVID-19, including the preliminary available results. We also discuss the potential of anticoagulant drugs to target the thromboinflammation described in patients with severe COVID-19.
Keywords: Anticoagulant; COVID-19; Coagulation; Deep venous thrombosis; Pulmonary embolism; Thromboprophylaxis.
. 2021 Jun 3;106883.
doi: 10.1016/j.vph.2021.106883. Online ahead of print.
Thromboprophylaxis strategies to improve the prognosis of COVID-19
Laurent Bertoletti[SUP] 1 [/SUP], Behnood Bikdeli[SUP] 2 [/SUP], Stéphane Zuily[SUP] 3 [/SUP], Marc Blondon[SUP] 4 [/SUP], Patrick Mismetti[SUP] 5 [/SUP]
Affiliations
- PMID: 34091065
- DOI: 10.1016/j.vph.2021.106883
Abstract
The outbreak of 2019 novel coronavirus disease (Covid-19) has deeply challenged the world population, but also our medical knowledge. Special attention has been paid early to an activation of coagulation, then to an elevated rate of venous thromboembolism (VTE) in patients hospitalized with severe COVID-19. These data suggested that anticoagulant drugs should be evaluated in the treatment of patients with COVID-19. The publication of unexpected high rates of VTE in patients hospitalized with COVID-19, despite receiving thromboprophylaxis, open the way to dedicated trials, evaluating modified regimens of thromboprophylaxis. Moreover, the further improvement in our comprehension of the disease, particularly the pulmonary endothelial dysfunction increased the hope that anticoagulant drugs may also protect patients from pulmonary thrombosis. In this comprehensive review, we cover the different situations where thromboprophylaxis standard may be modified (medically-ill inpatients, ICU inpatients, outpatients), and describe some of the current randomized controls trials evaluating new regimens of thromboprophylaxis in patients with COVID-19, including the preliminary available results. We also discuss the potential of anticoagulant drugs to target the thromboinflammation described in patients with severe COVID-19.
Keywords: Anticoagulant; COVID-19; Coagulation; Deep venous thrombosis; Pulmonary embolism; Thromboprophylaxis.